Evidence map›Paper›PMID 22882218›Full record

ReviewExpert review of clinical immunology2012

Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Matthew N Meriggioli, Donald B Sanders

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 3 syntheses or guidelines pooled it, 177 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Beyond the antibodies: serum metabolomic profiling of myasthenia gravis.Metabolomics : Official journal of the Metabolomic Society · 2019
    Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Nipocalimab Dose Selection in Generalized Myasthenia Gravis.CPT: pharmacometrics & systems pharmacology · 2025
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Observational
  18. Review
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Matthew N MeriggioliDepartment of Neurology and Rehabilitation, College of Medicine, University of Illinois Hospital and Health Sciences System, Chicago, IL 60612, USA. mmerig@uic.edu
Donald B Sanders
Duke Medical Center · USUniversity of Illinois Chicago · US

Funding

Immunoregulation of Experimental Autoimmune Myasthenia GravisK08NS058800 · NINDS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MERIGGIOLI, MATTHEW NICHOLAS · 2007 to 2011
$886k
NINDS NIH HHS K08 NS058800NINDS NIH HHS K08NS058800
6 · The paper itself

Abstract

Myasthenia gravis is an autoimmune disorder of the neuromuscular junction. A number of molecules, including ion channels and other proteins at the neuromuscular junction, may be targeted by autoantibodies leading to abnormal neuromuscular transmission. In approximately 85% of patients, autoantibodies, directed against the postsynaptic nicotinic acetylcholine receptor can be detected in the serum and confirm the diagnosis, but in general, do not precisely predict the degree of weakness or response to therapy. Antibodies to the muscle-specific tyrosine kinase are detected in approximately 50% of generalized myasthenia gravis patients who are seronegative for anti-acetylcholine receptor antibodies, and levels of anti-muscle-specific tyrosine kinase antibodies do appear to correlate with disease severity and treatment response. Antibodies to other muscle antigens may be found in the subsets of myasthenia gravis patients, potentially providing clinically useful diagnostic information, but their utility as relevant biomarkers (measures of disease state or response to treatment) is currently unclear.

Indexed as

AutoantibodiesAutoantigensAutoimmune DiseasesHumansMuscle, SkeletalMyasthenia GravisReceptor Protein-Tyrosine KinasesReceptors, CholinergicReceptors, NicotinicAutoantibodiesAutoantigensMUSK protein, humanReceptor Protein-Tyrosine KinasesReceptors, CholinergicReceptors, Nicotinic

Identifiers

PMID22882218
PMCPMC3505488
OpenAlexW2111456409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.